Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Neurofibromatosis 1 2Carcinoma, Hepatocellular 2Weight Loss 1Ulcer 1Tongue Neoplasms 1Stomatitis 1Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Salivary Gland Neoplasms 1Radiation-Induced Mucositis 1Radiation Pneumonitis 1Pseudomyxoma Peritonei 1Primary Graft Dysfunction 1Peripheral Nervous System Diseases 1Ovarian Neoplasms 1Ototoxicity 1Neoplasms, Cystic, Mucinous, and Serous 1Muscular Atrophy 1Mucositis 1Melanoma 1Lymphoma, Non-Hodgkin 1Lung Neoplasms 1Lung Diseases, Interstitial 1Liver Neoplasms 1Liver Failure, Acute 1Liver Failure 1Liver Diseases 1Leukemia, Myeloid, Acute 1Hodgkin Disease 1Head and Neck Neoplasms 1

Interventions

atezolizumab 2Nivolumab 2cobimetinib 1Specimen Handling 1Oxaliplatin 1Magnetic Resonance Spectroscopy 1Leucovorin 1Ipilimumab 1Immunoglobulin G 1Fluorouracil 1Disulfides 1Chemoradiotherapy 1CTLA-4 Antigen 1Bromelains 1Bevacizumab 1Acetylcysteine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Adenocarcinoma, Mucinous × Acetylcysteine × Clear all
NCT03976973 2022-03-15

BromAc for Recurrent Peritoneal Mucinous Tumour or Pseudomyxoma Peritonei

Mucpharm Pty Ltd

Phase 2 Unknown
62 enrolled

Adenocarcinoma, Mucinous, Pseudomyxoma Peritonei, Neoplasms, Cystic, Mucinous, and Serous

Data powered by HemOnc (CC BY 4.0) Colophon âš¡